SearchBar Icon

Technological Advancements for Drug Development to Boost the HAE Pipeline Growth

Published Date:   November 2017

HAE currently exhibits a proliferating pipeline with 20 drug candidates, P&S Intelligence

HAE Therapeutics Pipeline in 2017

The study analyzed that HAE therapeutics pipeline comprises 20 drug candidates in different stages of development. HAE is a disease characterized by repeated incidents of swelling (angioedema). Some of the common body areas that get affected due to this disease include intestinal tract, face, limbs, and airway. The stress can cause a heart attack, but most often in the patients suffering from HAE, the swelling occurs with an unknown trigger.

Access Report Summary with Detailed TOC on "Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis" at:

Insights on pipeline segments

According to the research findings, most of the drug candidates of the HAE are being derived from the natural sources. The natural sources consist of various molecules such as gene therapies, biologicals, and RNA.

Technological Advancements for Drug Development to Boost the HAE Pipeline Growth

Most of the companies have developed novel technologies for the development of drug candidates for the treatment of HAE. For instance, Arrowhead Pharmaceuticals, Inc. has established a drug discovery, and development platform that has broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies. These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk, relative to traditional approaches. These technological advancements act as a key driver for pipeline growth.

Positive Clinical Results of HAE Therapeutics Candidates

The positive clinical results of HAE drug candidates are driving the pipeline growth. For instance, Attune Pharmaceuticals, Inc., announced the Pre-Clinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. Studies demonstrated that ATN-249 was highly selective and potent at plasma kallikrein inhibition in both biochemical inhibition and contact activation assays. Therefore, the positive clinical results of the compounds under the development for the treatment of HAE, are fueling the research and development investment being made by the players developing drugs for the treatment of HAE.

Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.

HAE Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company